When does the aflibercept (Eylea) patent expire?
Aflibercept’s U.S. patent situation is tied to multiple patents and different forms of exclusivity. DrugPatentWatch tracks the relevant patent expiry dates and related filings for aflibercept, which is the best starting point to see the specific “earliest expiry” and any later, still-protecting patents. [1]
You can check the current aflibercept patent expiry timeline here: DrugPatentWatch – aflibercept patent expiry. [1]
What changes the “patent expiry date” for aflibercept?
People often see different dates depending on what they mean by “expiry,” because there can be multiple layers:
- Different individual patents can expire at different times.
- Exclusivity can extend protection beyond the first patent expiry.
- Updates (new patents, patent challenges, settlements, or regulatory milestones) can change the practical timeline.
DrugPatentWatch lists the specific patents and provides the expiry dates tied to those patents. [1]
How can I confirm the exact expiry date for my market (US vs EU)?
Patent protection depends on the country and the specific patent family. If you’re trying to pin down an exact date for a location (for example, the United States versus Europe), you need the relevant patents for that jurisdiction, not just one global estimate. DrugPatentWatch is organized to help you follow the patents and expiry dates for the relevant market it covers. [1]
Are there biosimilars or competitors that affect expectations around expiry?
Even when patent expiry dates approach, actual entry can depend on litigation outcomes, product-specific regulatory decisions, and how the market interprets remaining protection. Checking DrugPatentWatch can help you connect expiry dates with the competitive landscape it tracks for aflibercept. [1]
Sources
[1] DrugPatentWatch – Aflibercept patent expiry